ReviewOncologic photodynamic therapy: Clinical strategies that modulate mechanisms of action
Introduction
The relative clinical simplicity of PDT has brought this oncologic intervention to a worldwide audience [1]. However, this straightforward elegance of drug/light reaction should not be misconstrued. Successful clinical PDT is a complex interplay of light and photosensitizers interacting in time and space to create the oxygen dependent, tumor ablative photodynamic reaction [2]. Yet in the clinic, PDT has evolved into a rote application of prescribed drug dose followed by a fixed light dose with both parameters set to maximize tumor ablation, even at the cost of potentially excessive normal tissue damage. In reality the clinician/scientist has multiple tools available to not only improve tumor response but also to minimize morbidity [3]. Furthermore, the clinician may also be able to modulate immune response through various manipulations of the actual photodynamic therapy [4]. This paper will challenge all involved with PDT to examine the potential to enhance therapy through a re-evaluation of both PDT components and mechanisms of action. Clinically relevant alterations of current treatment paradigms will also be examined on their ability to potentiate PDT.
Section snippets
Clinical and historical perspectives
Currently, clinical PDT involves application of a PS agent followed by illumination at an appropriate wavelength and intensity of light to activate the PS [5]. Ideally, this will result in an ablative photodynamic reaction that eliminates the lesion but spares normal tissue.
Historically, intravenous PS agents were developed and a therapeutic paradigm of a single illumination for ablation followed [6]. This may have been due to the difficulty of achieving adequate illumination, particularly for
Drugs, light, reaction
To better understand the mechanisms of action of PDT and appreciate how the currently available tools for PDT may be manipulated to improve the therapeutic ratio, we will examine PS, illumination and the PDR separately. This will ultimately allow us to speculate on the interplay of these potential variables for clinical enhancement.
Mechanisms
Once the PDR has occurred, well described but incompletely understood pathways are activated which impact tumor and normal tissue survival [59]. While the actual reaction is measured in nanoseconds and treatment time in minutes, response and outcome may take days, months or even years to occur. This section will describe the general response to PDT and then specific outcomes on tumor and normal tissue, vascular supply and immune response to PDT. Upon generation of the PDR both tumor and normal
Clinical tools
Currently, clinical PDT treatment protocol involves a standard dose of drug, a standard light dose and a standard drug-light interval. Yet clinical outcomes may vary tremendously. This is probably due to the individual patient's metabolism of the PS, lack of light homogeneously illuminating the target and a lack of dosemetric tools to help guide therapy. However, the clinician has a number of tools available to improve outcomes. An informed/experienced PDT clinician should consider not only the
Translation of the mechanisms of PDT to optimize results today
Upon consideration, it is clear that, while in the laboratory situation drug and light dose can be measured to achieve the optimal PDR results, in clinical PDT there are many variables that cannot yet be measured which affect outcomes. This is even more the case in cancer. Even for a specific cancer such as that of endobronchial, with all its sub types and variations in morphology and physical characteristics, it would be illogical to follow rigidly a “standard light/drug dose”. The standard is
Conflict of interest
None.
Acknowledgement
The authors would wish to acknowledge, with thanks, the contribution of Mrs Kate Dixon who read the manuscript and gave appropriate advice.
References (111)
- et al.
Clinical PD/PDT in North America: an historical review
Photodiagnosis and Photodynamic Therapy
(2004) - et al.
On the mechanism of the tumour-localising effect in photodynamic therapy
Journal of Photochemistry & Photobiology B: Biology
(1994) Photodynamic therapy (PDT) of malignant tumors
Critical Reviews in Oncology-Hematology
(1984)Lasers and light sources for PDT: past, present and future
Photodiagnosis and Photodynamic Therapy
(2004)Photodynamic therapy for lung cancer – a review of 19 years’ experience
Journal of Photochemistry & Photobiology B: Biology
(1998)- et al.
Photodynamic therapy. Its use in the management of bronchogenic carcinoma
Clinics in Chest Medicine
(1995) Dosimetric concepts for PDT
Photodiagnosis & Photodynamic Therapy
(2008)- et al.
Photofrin photodynamic therapy: 2.0 mg/kg or not 2.0 mg/kg that is the question
Photodiagnosis & Photodynamic Therapy
(2008) - et al.
Oncologic photodynamic therapy photosensitizers: a clinical review
Photodiagnosis & Photodynamic Therapy
(2010) - et al.
Photodiagnosis for cutaneous malignancy: a brief clinical and technical review
Photodiagnosis & Photodynamic Therapy
(2008)
The present and future role of photodynamic therapy in cancer treatment
Lancet Oncology
Mechanisms in photodynamic therapy: Part one: Photosensitizers, photochemistry and cellular localization
Photodiagnosis and Photodynamic Therapy
Bio-nanotechnology and photodynamic therapy – state of the art review
Photodiagnosis and Photodynamic Therapy
Mechanisms in photodynamic therapy: Part three: Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction
Photodiagnosis and Photodynamic Therapy
Photodynamic therapy targeted to tumor-induced angiogenic vessels
Cancer Letters
TAT-mediated photochemical internalization results in cell killing by causing the release of calcium into the cytosol of cells
Biochimica et Biophysica Acta
Mitochondria-based photodynamic anti-cancer therapy
Advanced Drug Delivery Reviews
The importance of fluence rate in photodynamic therapy: is there a parallel with ionizing radiation dose-rate effects?
Radiotherapy & Oncology
Photodiagnosis & Photodynamic Therapy
Death pathways associated with photodynamic therapy
Medical Laser Application
Induction of Hsp60 by photofrin-mediated photodynamic therapy
Journal of Photochemistry & Photobiology B: Biology
Molecular effectors of multiple cell death pathways initiated by photodynamic therapy
Biochimica et Biophysica Acta
Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT
Journal of Photochemistry & Photobiology B: Biology
New insights into the mechanisms for photodynamic therapy-induced cancer cell death
International Review of Cell & Molecular Biology
Photodynamic therapy induces selective extravasation of macromolecules: insights using intravital microscopy
Journal of Photochemistry & Photobiology B: Biology
Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors
Cancer Letters
Photodynamic therapy
Journal of the National Cancer Institute
The photobiology of photodynamic therapy: cellular targets and mechanisms
Radiation Research
A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute
Journal of Clinical Laser Medicine and Surgery
The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases
European Journal of Cardio-Thoracic Surgery
A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma
Lasers in Surgery & Medicine
Long-term outcomes following Foscan[REGISTERED]-PDT of basal cell carcinomas
Lasers in Surgery & Medicine
Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck
Lasers in Surgery & Medicine
Optimization of treatment parameters for Foscan-PDT of basal cell carcinomas
Lasers in Surgery & Medicine
New technology for deep light distribution in tissue for phototherapy
Cancer Journal
Future of oncologic photodynamic therapy
Future Oncology
Photodynamic therapy and neoplastic disease
Oncology Research
Clinical outcomes of photodynamic therapy for head-and-neck cancer
Technology in Cancer Research & Treatment
The role of subcellular localization in initiation of apoptosis by photodynamic therapy
Photochemistry & Photobiology
mTHPC-based photodynamic therapy induction of autophagy and apoptosis in cultured cells in relation to mitochondria and endoplasmic reticulum stress
International Journal of Oncology
Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells
Autophagy
Characterization of intra-tumoral porphyrin following injection of hematoporphyrin derivative or its purified component
Photochemistry & Photobiology
Structure and biodistribution relationships of photodynamic sensitizers
Photochemistry & Photobiology
In vivo transport and pharmacokinetic behavior of tumour photosensitizers
Ciba Foundation Symposium
The role of the peripheral benzodiazepine receptor in photodynamic activity of certain pyropheophorbide ether photosensitizers: albumin site II as a surrogate marker for activity
Photochemistry & Photobiology
Targeting of the vascular system of solid tumours by photodynamic therapy (PDT)
Photochemical & Photobiological Sciences
Antivascular tumor eradication by hypericin-mediated photodynamic therapy
Photochemistry & Photobiology
Artifacts in fluorescence emission spectroscopy related to wood's anomaly
Photochemistry & Photobiology
The distribution of porphyrins with different tumour localising ability among human plasma proteins
British Journal of Cancer
Endoplasmic reticulum and golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells
British Journal of Cancer
Cited by (0)
- 1
Membre Associe Academie de Chirurgie (Paris).